Umoja Biopharma raised $100M in a Series C funding round led by Double Point Ventures and DCVC Bio to further develop CAR T-cell immunotherapy treatments.
Amount Raised
$100 Million
Round Type
Series C
SeattleBiotechnologyTherapeuticsInvestors
Description
Umoja Biopharma has successfully closed a $100 million Series C funding round to advance its innovative CAR T-cell immunotherapy technologies. The investment will help the Seattle-based startup enhance its cancer-fighting treatments for both blood and organ-based tumors.
Quick answer
Umoja Biopharma raised $100 Million in a Series C round, dated January 14, 2025. Investors: ARK Invest, Cormorant Asset Management, Mpm Capital, Qiming Venture Partners USA, RTW Investments, Double Point Ventures and DCVC Bio. Umoja Biopharma is based in Seattle, Washington, United States.
- How much did Umoja Biopharma raise?
- Umoja Biopharma raised $100 Million in a Series C round on January 14, 2025.
- Who invested in Umoja Biopharma?
- ARK Invest, Cormorant Asset Management, Mpm Capital, Qiming Venture Partners USA, RTW Investments, Double Point Ventures and DCVC Bio are named as investors in this round.
- What does Umoja Biopharma do?
- Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity.
- Where is Umoja Biopharma based and how big is it?
- Umoja Biopharma is based in Seattle, Washington, United States. Fundz records about 191 employees.
- Who are the decision-makers at Umoja Biopharma?
- Fundz holds 1 contact at Umoja Biopharma. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Umoja Biopharma that raised within 45 days of this round, from Fundz verified event records.
- Eikon Therapeutics raised $351M (Series D) on February 26, 2025.
- Monument Therapeutics raised $1.1M (Seed) on February 25, 2025.
- Fuse Vectors raised $5.2M (Pre-Seed) on February 25, 2025.
- Solid IO raised $839K (Seed) on February 24, 2025.
- Humane Genomics raised an undisclosed amount (Seed) on February 21, 2025.
- Ceretas raised $1M (Seed) on February 21, 2025.
Who to call at Umoja Biopharma, and when
A new round usually means Umoja Biopharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Umoja Biopharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Umoja Biopharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Umoja Biopharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Umoja Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Umoja Biopharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.